Started as India’s first independent product development company, Rubicon Research has developed and scaled up several drug products. In 2016, we successfully scaled up our 100th product and have gone on to expand our development expertise with a commercial focus, leading to multiple product approvals and launches. We leverage our proprietary technologies and specialized formulation development skills to provide innovative solutions to complex delivery challenges. Rubicon Research has launched 40 SKUs, with over 1 billion extended units sold in the US in 2019. Additionally, we have 20 approvals and launches (across oral solids and ophthalmic formulations) in the pipeline for 2020.